SVB Financial Group (SIVB)
Dopo ore:
| Chiusura precedente | 295,62 |
| Aperto | 293,63 |
| Denaro | 295,50 x 900 |
| Lettera | 306,70 x 900 |
| Min-Max giorno | 292,50 - 305,01 |
| Intervallo di 52 settimane | 198,10 - 658,47 |
| Volume | |
| Media Volume | 1.078.000 |
| Capitalizzazione | 17,896B |
| Beta (5 anni mensile) | 1,48 |
| Rapporto PE (ttm) | 11,90 |
| EPS (ttm) | 25,42 |
| Prossima data utili | 20 apr 2023 |
| Rendimento e dividendo (forward) | N/D (N/D) |
| Data ex dividendo | 10 feb 1992 |
| Stima target 1A | 282,94 |
- GlobeNewswire
Lucira Health Secures Debt Facility of Up to $80 Million from Hercules Capital and Silicon Valley Bank
EMERYVILLE, Calif., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Lucira Health, Inc. ("Lucira Health" or "Lucira") (Nasdaq: LHDX), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits, today announced that on February 4, 2022, it entered into a debt facility of up to $80 million with Hercules Capital, Inc. (NYSE: HTGC) ("Hercules") and Silicon Valley Bank (NASDAQ: SIVB) ("SVB"). "This debt financing will provide Lucira l
- GlobeNewswire
Tarsus Completes Enrollment for the Pivotal Phase 3 Saturn-2 Trial of TP-03 to Treat Demodex Blepharitis and Secures $175 Million Credit Facility
Topline data expected in April 2022 from Saturn-2, the second Phase 3 pivotal trial of TP-03 and NDA submission remains on track for this year Credit facility with Hercules Capital and Silicon Valley Bank provides availability of non-dilutive capital IRVINE, Calif., Feb. 02, 2022 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today
